Update: First signals of 'Kick and Kill' potential
Interim data from the Phase II REDUC trial of Vacc-4x with romidepsinprovide initial hints at the potential for this combination to reactivate and
destroy latent HIV reservoirs. Although early stage and from only a few
patients, we believe these signals are encouraging for Vacc-4x’s future, in
particular as a functional cure for HIV. Full data by YE15 will be needed to
confirm these trends and will be critical in determining the future
development for Vacc-4x. Our valuation is largely unchanged at NOK993m.
Solon Eiendom is a biotechnology company. Co.'s focus is the research and development of peptide based vaccines against viral diseases, primarily human immunodeficiency virus (HIV). As of Dec 31 2013, Co.'s clinical development pipeline comprised of two vaccine candidates for the treatment of HIV, Vacc-4X and Vacc-C5. Vacc-4X is being investigated in two phases II trials in collaboration with Celgene Inc.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.